Merck (Germany) and Thermo Fisher Scientific (US) are the leading players in the Apoptosis Assays Market

The ****** apoptosis assays market is projected to reach USD 5.9 billion by 2023 from USD 3.6 billion in 2018, at a CAGR of 10.5%.

The ****** apoptosis assays market is projected to reach USD 5.9 billion by 2023 from USD 3.6 billion in 2018, at a CAGR of 10.5%. Factors such as the rising incidence and prevalence of chronic and infectious diseases, growing funding for cancer research, growing cell-based research, and development of apoptosis-modulating drugs are driving the growth of this market. The emerging markets are expected to provide growth opportunities for players operating in the apoptosis assays market in the coming years. However, high investments required for research and development is expected to restrain the growth of this market to a certain extent during the forecast period.

Players in the ****** apoptosis assays market, such as Merck KGaA (Germany), Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Becton, Dickinson and Company (US), GE Healthcare (US), Danaher Corporation (US), Sartorius AG (Germany), Geno Technology (US), GeneCopoeia, Inc. (US), Bio-Techne Corporation(US), BioTek Instruments (US), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Canvax (Spain), Abnova (Taiwan), and Creative Bioarray (US) are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies of product launches, expansions, agreements, collaborations, and acquisitions.

To know about the assumptions considered for the study download the pdf brochure

Merck is the leading player in the apoptosis assay kits market. With regard to providing innovative products, Merck invests a significant amount of its sales revenue in R&D. In 2017, it invested around 14% of its sales revenue in R&D activities. This allows the company to extend its technological capabilities and provide superior-quality products, thereby helping it to achieve long-term growth. The company is also investing a large sum into its expansion projects to increase its production capacity and cater to a larger consumer base. In this regard, in 2018, the company invested USD 19 million in its new manufacturing and distribution center for the Life Science business in India. Similar investments have been made by the company in the last few years. The acquisition of Sigma-Aldrich significantly enhanced the company’s ****** presence and broadened its portfolio in the apoptosis assays market.

Thermo Fisher Scientific is the second-largest player in the ****** apoptosis assay kits market in 2018. The company offers a broad portfolio of apoptosis assays for flow cytometers, microplates, imaging, along with other consumables ranging from reagents to stains and dyes. The company’s stronghold in the market is largely attributed to its strong product portfolio and strong customer relations, owing to its strong sales and distribution network. It also leverages the advantage of three well-established brands—Thermo Scientific, Fisher Scientific, and Unity Lab Services. Additionally, its large number of production sites gives it a competitive advantage over other players in the apoptosis assays market. The company’s extensive R&D activities enable it to increase its depth of capabilities in technologies, software, and services. Moreover, its significant investment in R&D enables it to provide innovative products in the market space, thus enabling it to maintain and improve its competitive position in the apoptosis assays market. The company’s FDA and CE Mark-approved products have helped it to further enhance its presence in this market.

Thermo Fisher also focuses on geographic expansions. In line with this, the firm has opened new GMP facilities in the US and South Korea in 2016. Moreover, the company aims to strengthen its presence in selected geographies in the Asia Pacific region, undertaking various organic and inorganic growth strategies.

Related Reports:

Apoptosis Assays Market by Product (Caspase, Annexin V, DNA Fragmentation, Mitochondrial Assay), Detection Technology (Flow Cytometry, Florescence microscopy), Application (Stem Cell, Discovery & Development, Clinical Research) – ****** Forecast to 2023